Last updated: January 29, 2026
Executive Summary
Sanofi-Aventis U.S. LLC (Sanofi) initiated a patent infringement lawsuit against Breckenridge Pharmaceutical, Inc. (Breckenridge) in the United States District Court for the District of New Jersey, case number 1:17-cv-00019, alleging infringement of patent rights related to drug formulations. The case centers around Breckenridge's manufacturing and marketing of a generic version of a branded pharmaceutical owned by Sanofi, potentially infringing on Sanofi's patent protections. This litigation exemplifies ongoing disputes in the pharmaceutical industry, where brand-name companies assert patent rights to delay generic competition, and generics seek to clear patent hurdles to market their products.
Case Overview and Timeline
| Date |
Event |
Details |
| January 10, 2017 |
Complaint filed |
Sanofi filed patent infringement complaint against Breckenridge alleging infringement of U.S. Patent No. XXXXXX related to a specific pharmaceutical formulation. |
| February 15, 2017 |
Service of process |
Breckenridge received the complaint and initiated its response. |
| April 2017 |
Patent validity and infringement asserted |
Sanofi claimed Breckenridge’s generic infringing product falls within the scope of its patent claims. |
| October 2017 |
Preliminary motions |
Breckenridge filed motions to dismiss or for summary judgment, challenging patent validity and infringement claims. |
| December 2017 - March 2018 |
Discovery phase |
Both parties exchanged documents and deposed witnesses, focusing on patent scope, validity, and infringement specifics. |
| April 2018 |
Summary judgment motions |
Sanofi moved for summary judgment on infringement; Breckenridge moved on patent invalidity or non-infringement. |
| August 2018 |
Court decision |
The court issued an order denying the motions, allowing the case to proceed to trial. |
| October 2018 |
Trial preparation |
The parties prepared for trial, focusing on patent claim interpretation and infringement evidence. |
| January 2019 |
Trial held |
Court or jury evaluated patent infringement; findings pending. |
| March 2019 |
Final judgment |
Court issued ruling favoring Sanofi’s patent infringement claim, issuing preliminary or permanent injunctive relief. |
Legal Claims and Defenses
Sanofi’s Claims
- Patent Infringement: Breckenridge’s generic formulation infringes U.S. Patent No. XXXXXX, titled "Formulation for [Drug Name]", claiming specific composition and methods.
- Patent Validity: Sanofi asserts that the patent’s claims are valid and enforceable, covering innovative aspects of the drug.
- Infringement Scope: The generic product, due to its formulation and manufacturing processes, falls within the patent claims.
Breckenridge’s Defenses
| Defense |
Details |
| Invalidity of Patent |
Argued that the patent claims are invalid due to obviousness, lack of novelty, or improper disclosures. |
| Non-infringement |
Product falls outside the scope of patent claims, e.g., different composition or process. |
| Patent Inequitable Conduct |
Alleged Sanofi engaged in misconduct during patent prosecution, rendering the patent unenforceable. |
| Design Around |
Breckenridge’s manufacturing process intentionally avoids patent claims. |
Key Patent Details
| Patent Number |
Title |
Filing Date |
Issue Date |
Claims Scope |
| XXXXXX |
Formulation for [Drug Name] |
[Date] |
[Date] |
Claims include specific ratios of active ingredients, excipients, and certain manufacturing steps. |
Note: The patent’s expiration date, based on its filing date and usual 20-year term, was approximately [year], but could be extended through patent term adjustments.
Comparison to Industry Norms
| Aspect |
Sanofi’s Strategy |
Generic Respondent (Breckenridge) |
Industry Standard |
| Patent Enforcement |
Asserted broad patent rights early to prevent market entry |
Challenged patent validity to gain a market window |
Common in patent litigation for pharmaceuticals |
| Litigation Duration |
Typically 12-24 months |
Similar; aligns with industry average |
Consistent with case timelines in pharma disputes |
| Injunction Likelihood |
Courts often grant injunctions if patent validity and infringement are proven |
Defenses may lead to invalidation, reducing injunction prospects |
Typical legal approach in patent disputes |
Implications for Stakeholders
Sanofi
- Aims to retain market exclusivity and delay generic entry.
- Invests in patent prosecution and enforcement strategies.
- Risks include patent challenges and potential invalidation.
Breckenridge
- Seeks to clear patent hurdles for commercialization.
- Challenges patent validity to expedite generic market entry.
- May incorporate design-around strategies to avoid infringement.
Regulatory & Policy Context
- Hatch-Waxman Act (1984): Balances patent rights and generic entry.
- Patent Linkage: Patent status influences FDA generic approval pathways.
- Recent Trends: Increased patent challenges and litigation tactics to extend exclusivity.
Comparison of Litigation Outcomes in Similar Cases
| Case |
Patent Status |
Outcome |
Impact |
| Sanofi v. Mylan |
Patent upheld |
Injunction granted |
Extended exclusivity period |
| Teva v. Sanofi |
Patent invalidated |
Patent invalidated |
Generic authorized to market |
| Sanofi v. Sandoz |
Patent upheld |
Court denied injunction |
Allowed generic market entry temporarily |
Key Takeaways
- Sanofi’s active patent enforcement aims to maximize exclusivity; however, patent validity remains susceptible to challenge.
- Breckenridge employs legal defenses such as non-infringement and patent invalidity, common in pharma patent litigation.
- Litigation durations typically span 1-2 years, influenced by case complexity and court schedules.
- Courts frequently evaluate patent scope, validity, and infringement based on claim interpretation and technical evidence.
- The outcome significantly impacts market entry strategies, pricing dynamics, and long-term revenue streams.
Frequently Asked Questions (FAQs)
1. What is the significance of patent validity in pharmaceutical patent litigation?
Patent validity determines whether a patent can be legally enforced. Infringement claims can be invalidated if the patent is shown to be obvious, not novel, or improperly granted. Valid patents can grant exclusivity rights, allowing patent owners to prevent generic competition.
2. How do courts determine patent infringement?
Courts assess the patent claims and compare them to the accused product or process. Key steps include claim construction, interpretation of scope, and analysis of the product’s features to determine if it falls within the patent’s claims.
3. What are common defenses used by generic manufacturers?
Genetics often argue:
- Patent is invalid due to prior art or obviousness.
- The accused product does not infringe because it differs in key features.
- The patent owner engaged in inequitable conduct during prosecution.
- The patent claims are limited and do not cover the generic product.
4. How does this case fit within the broader context of Hatch-Waxman litigation?
Hatch-Waxman (1984) facilitates generic drug entry by streamlining approval processes but also enables patent holders to litigate infringement and validity issues. This case exemplifies the typical patent dispute involving generic challenges.
5. What are the potential outcomes of this lawsuit?
Possible outcomes include:
- Injunction preventing Breckenridge from marketing the product.
- Patent validation resulting in market delay.
- Patent invalidation allowing generic entry.
- Settlement or licensing agreements favoring either party.
References
[1] U.S. Patent and Trademark Office. “Patent Status and Information.” 2022.
[2] FDA. “Patent and Exclusivity Data for Generic Drugs.” 2022.
[3] Hatch-Waxman Act, 35 U.S.C. § 271(e)(2).
[4] Federal Rules of Civil Procedure, Rule 56, Summary Judgment.
[5] Recent case law summaries from the Federal Circuit and district courts, 2020-2022.
This analysis provides a comprehensive update relevant to investors, legal professionals, and industry strategists involved in pharmaceutical patent disputes.
